Financial Tear Sheet

Corporate Profile

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of nearly $9.5 billion for 2016. To learn more about LabCorp, visit www.labcorp.com,and to learn more about Covance Drug Development, visit www.covance.com.

More Information

Primary IR Contact
Scott Frommer
Vice President, Investor Relations
Laboratory Corporation of America Holdings
Phone: 336-436-5076
Fax: 336-436-1569
E-mail: investor@labcorp.com

Stock Performance
LH (Common)
ExchangeNYSE (US Dollar)
Price$150.36
Change (%) Stock is Down 0.66 (0.44%)
Volume468,509
52 Week Low$123.36
Market Cap$15,306,648,000
Rolling EPS7.17
PE Ratio20.97
Shares Outstanding101,800,000
Data as of 11/17/17 4:02 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: LH.  Currently trading at $150.36 with a 52 week high of $164.22 and a 52 week low of $123.36.
Recent News & Events
11/15/17 - 8:46 a.m.
LabCorp Announces New Expanded Use for PD-L1 Test with Bristol-Myers Squibb’s OPDIVO®
11/13/17 - 8:31 a.m.
LabCorp Receives 2017 Partnership Award from Be The Match®
11/13/17 - 7:30 a.m.
LabCorp Earns 100 Percent on Human Rights Campaign Foundation’s 16th Annual Scorecard on LGBTQ Workplace Equality
There are currently no events scheduled.
Analyst Estimates / Ratings
Mean Recommendation: 2.2

Buy
SellStrong Buy
EPS Trend
  Current30 Days Ago90 Days Ago
QTRDec 172.382.432.38
QTRMar 182.382.382.37
QTRJun 182.672.712.69
QTRSep 182.682.692.69
FYDec 179.539.539.50
FYDec 1810.3610.4410.39
SEC Filings
Filing DateForm
11/15/178-K XBRL SEC Filing Unavailable
11/13/178-K XBRL SEC Filing Unavailable
11/13/178-K XBRL SEC Filing Unavailable
11/07/178-K XBRL SEC Filing Unavailable
Corporate Governance
David P.  KingChairman and Chief Executive Officer
Glenn A. EisenbergExecutive Vice President and Chief Financial Officer
Gary M. HuffChief Executive Officer, LabCorp Diagnostics
John D.  RatliffChief Executive Officer, Covance Drug Development
Lance V. BerberianSenior Vice President and Chief Information Officer
Edward T. DodsonSenior Vice President and Chief Accounting Officer
F. Samuel Eberts IIISenior Vice President, Chief Legal Officer and Secretary
Lisa J. UthgenanntChief Human Resources Officer
Ownership Summary
Shareholders
 HoldersValue ($MM)% O/SShares
Institution97014,576.8494.496,695,912
Mutual Fund1,3427,041.4345.546,648,393
Insider *1755.670.4365,943
*Insider values reflect direct beneficial ownership.
Top Holders
 Shares Held% O/SShare ChangeFiling Date
The Vanguard Group, Inc.10,397,02410.235,13309/30/17
BlackRock Institutional Trust Company, N.A.5,645,8145.576,62309/30/17
Boston Partners4,619,6704.529,29809/30/17
State Street Global Advisors (US)4,431,3094.3-156,94309/30/17
Glenview Capital Management, LLC2,908,1882.8243,20009/30/17
Nordea Funds Oy2,342,1072.3-354,74409/30/17
Iridian Asset Management LLC1,581,9661.5-18,31209/30/17
HealthCor Management, L.P.1,572,2901.5197,29009/30/17
Fidelity Management & Research Company1,473,3931.4-280,71309/30/17
Dimensional Fund Advisors, L.P.1,409,9411.414,90109/30/17